Cambridge, UK –26 September 2024–AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer…Original Article
Tagrisso Approved in the US for Patients with Unresectable, Stage III EGFR-Mutated Lung Cancer
